• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者群体中万古霉素的药代动力学:年龄、性别和体重的影响。

Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight.

作者信息

Ducharme M P, Slaughter R L, Edwards D J

机构信息

Department of Pharmacy Practice, College of Pharmacy and Allied Health Professions, Wayne State University, Detroit, Michigan.

出版信息

Ther Drug Monit. 1994 Oct;16(5):513-8. doi: 10.1097/00007691-199410000-00013.

DOI:10.1097/00007691-199410000-00013
PMID:7846752
Abstract

The effects of age, gender, and body weight on the pharmacokinetics of vancomycin were examined using data collected as part of routine therapeutic drug monitoring in patients. One thousand eighty-five sets of steady-state peak and trough serum concentrations obtained from 704 different patients were used to calculate elimination rate constant (k), volume of distribution (V), and clearance (Cl) using a one-compartment model. The median half-life of vancomycin was 6.5 h. Clearance was significantly correlated with creatinine clearance as estimated using the Cockcroft-Gault equation [Cl = 0.771 (Clcr) + 18.9; r = 0.63]. V averaged 0.69 L/kg ideal body weight (IBW) with increased values in females, patients over age 60, and obese patients. V ranged from 0.58 L/kg IBW in normal weight males under age 40 to 1.17 L/kg IBW in obese females over age 60. V was not different in underweight patients and those of normal weight (43.8 vs. 44.4 L). Regression analysis indicated that V was more predictable in women than in men and that vancomycin distributed into excess body weight (EBW) to a greater extent in women. However, the correlation coefficients from multiple regression analysis of V with IBW, EBW, and age did not exceed 0.60, and the high root mean square error values of 11-15 L suggest considerable variability in V is not accounted for by these factors alone. Despite these limitations, dosing of vancomycin may be improved by adjusting initial estimates of V for patient age, gender, and obesity.

摘要

利用患者常规治疗药物监测收集的数据,研究了年龄、性别和体重对万古霉素药代动力学的影响。从704例不同患者中获取的1085组稳态峰浓度和谷浓度血清样本,采用一室模型计算消除速率常数(k)、分布容积(V)和清除率(Cl)。万古霉素的中位半衰期为6.5小时。清除率与使用Cockcroft - Gault方程估算的肌酐清除率显著相关[Cl = 0.771(Clcr)+ 18.9;r = 0.63]。V平均为0.69 L/kg理想体重(IBW),女性、60岁以上患者和肥胖患者的值升高。V范围从40岁以下正常体重男性的0.58 L/kg IBW到60岁以上肥胖女性的1.17 L/kg IBW。体重过轻患者和正常体重患者的V无差异(43.8对44.4 L)。回归分析表明,女性的V比男性更具可预测性,且万古霉素在女性体内向多余体重(EBW)的分布程度更大。然而,V与IBW、EBW和年龄的多元回归分析的相关系数不超过0.60,11 - 15 L的高均方根误差值表明这些因素单独无法解释V的显著变异性。尽管存在这些局限性,但通过根据患者年龄、性别和肥胖情况调整V的初始估计值,万古霉素的给药方案可能会得到改善。

相似文献

1
Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight.患者群体中万古霉素的药代动力学:年龄、性别和体重的影响。
Ther Drug Monit. 1994 Oct;16(5):513-8. doi: 10.1097/00007691-199410000-00013.
2
Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.万古霉素在疑似或确诊金黄色葡萄球菌感染的极度肥胖患者中的药代动力学。
Pharmacotherapy. 2015 Feb;35(2):127-39. doi: 10.1002/phar.1531. Epub 2015 Feb 3.
3
Vancomycin pharmacokinetics in spinal cord injured patients: a comparison with age-matched, able-bodied controls.脊髓损伤患者的万古霉素药代动力学:与年龄匹配的健全对照者的比较。
J Spinal Cord Med. 1995 Oct;18(4):233-5. doi: 10.1080/10790268.1995.11719401.
4
Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation.新生儿和婴儿的万古霉素药代动力学:一项回顾性评估。
Ann Pharmacother. 1993 Apr;27(4):490-6. doi: 10.1177/106002809302700417.
5
Population pharmacokinetics of vancomycin in Japanese adult patients.日本成年患者中万古霉素的群体药代动力学
Ther Drug Monit. 1998 Apr;20(2):139-48. doi: 10.1097/00007691-199804000-00003.
6
Concordance of Vancomycin Population-Predicted Pharmacokinetics with Patient-Specific Pharmacokinetics in Adult Hospitalized Patients: A Case Series.万古霉素群体药代动力学与成年住院患者个体药动学的一致性:一项病例系列研究。
Drugs R D. 2020 Jun;20(2):83-93. doi: 10.1007/s40268-020-00298-0.
7
Comparing two predictive methods for determining serum vancomycin concentrations at a Veterans Affairs Medical Center.比较退伍军人事务医疗中心两种用于测定血清万古霉素浓度的预测方法。
Am J Health Syst Pharm. 2006 Oct 1;63(19):1872-5. doi: 10.2146/ajhp060138.
8
Population pharmacokinetics of vancomycin in Thai patients.泰国患者中万古霉素的群体药代动力学。
ScientificWorldJournal. 2012;2012:762649. doi: 10.1100/2012/762649. Epub 2012 Apr 1.
9
Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.美罗培南持续输注在肾功能稳定和不稳定的超重、肥胖及病态肥胖患者中的药代动力学和药效学:迈向严重革兰氏阴性菌感染治疗剂量优化的一步。
Clin Pharmacokinet. 2015 Sep;54(9):933-41. doi: 10.1007/s40262-015-0266-2.
10
Evaluation of Vancomycin Prediction Methods Based on Estimated Creatinine Clearance or Trough Levels.基于估计的肌酐清除率或谷浓度水平的万古霉素预测方法评估
Ther Drug Monit. 2016 Feb;38(1):120-6. doi: 10.1097/FTD.0000000000000250.

引用本文的文献

1
Development and validation of a population pharmacokinetic model of vancomycin for patients of advanced age.老年患者万古霉素群体药代动力学模型的建立与验证
J Pharm Health Care Sci. 2025 Mar 12;11(1):18. doi: 10.1186/s40780-025-00423-8.
2
Prediction of vancomycin plasma concentration in elderly patients based on multi-algorithm mining combined with population pharmacokinetics.基于多算法挖掘结合群体药代动力学的老年患者万古霉素血药浓度预测。
Sci Rep. 2024 Nov 8;14(1):27165. doi: 10.1038/s41598-024-78558-1.
3
Combatting Antibiotic-Resistant : Discovery of TST1N-224, a Potent Inhibitor Targeting Response Regulator VraRC, through Pharmacophore-Based Screening and Molecular Characterizations.
对抗抗生素耐药性:通过基于药效团的筛选和分子特征研究发现针对反应调节子 vraRC 的强效抑制剂 TST1N-224。
J Chem Inf Model. 2024 Aug 12;64(15):6132-6146. doi: 10.1021/acs.jcim.4c01046. Epub 2024 Jul 30.
4
Characterizing Day 1 Area Under the Curve Following Vancomycin Loading Dose Administration in Adult Hospitalized Patients Using Non-Trapezoidal Linear Pharmacokinetic Equations: A Retrospective Observational Study.使用非梯形线性药代动力学方程表征成人住院患者万古霉素负荷剂量给药后第1天的曲线下面积:一项回顾性观察研究。
Infect Dis Ther. 2024 Aug;13(8):1807-1819. doi: 10.1007/s40121-024-01004-2. Epub 2024 Jun 26.
5
Vancomycin population pharmacokinetics and dosing proposal for the initial treatment in obese adult patients.肥胖成年患者初始治疗的万古霉素群体药代动力学及给药方案建议
Front Pharmacol. 2024 Jun 4;15:1364681. doi: 10.3389/fphar.2024.1364681. eCollection 2024.
6
Topical Application of Vancomycin Powder to Prevent Infections after Massive Bone Resection and the implantation of Megaprostheses in Orthopaedic Oncology Surgery.万古霉素粉末局部应用预防骨科肿瘤手术中大块骨切除及大假体植入术后感染
Malays Orthop J. 2024 Mar;18(1):125-132. doi: 10.5704/MOJ.2403.016.
7
The Association Between Serum Vancomycin Level and Clinical Outcome in Patients With Peritoneal Dialysis Associated Peritonitis.腹膜透析相关性腹膜炎患者血清万古霉素水平与临床结局的关联
Kidney Int Rep. 2023 Sep 17;8(12):2646-2653. doi: 10.1016/j.ekir.2023.09.013. eCollection 2023 Dec.
8
A Quasi-Experimental Evaluation of Single Trough-Based Area Under the Curve Guided Dosing on the Incidence of Vancomycin Associated Nephrotoxicity in Veteran Patients.基于单谷浓度曲线下面积指导给药对老年患者万古霉素相关性肾毒性发生率影响的准实验性评估
J Pharm Technol. 2023 Jun;39(3):123-133. doi: 10.1177/87551225231172349. Epub 2023 May 22.
9
Characteristics and calculations of paired vancomycin measurements for determination of 24-h area-under-curve (AUC).用于测定24小时曲线下面积(AUC)的万古霉素配对测量值的特征与计算
Pract Lab Med. 2023 Jan 28;34:e00310. doi: 10.1016/j.plabm.2023.e00310. eCollection 2023 Mar.
10
Vancomycin dosing in an obese patient with acute renal failure: A case report and review of literature.肥胖合并急性肾衰竭患者的万古霉素给药:一例病例报告及文献综述
World J Clin Cases. 2022 Jun 26;10(18):6218-6226. doi: 10.12998/wjcc.v10.i18.6218.